
For four decades, the Alabama pharmaceutical entrepreneur kept returning to overlooked products, small teams and the difficult work between a molecule and a pharmacy shelf. His career is a study in patient execution - and in knowing when to sell.
The Montreal drugmaker is spending C$119.33 million to triple injectable capacity and sell its know-how to biotech companies. The bet turns an old factory discipline into a new growth engine - if quality and utilization keep pace.
They spent 20 years learning how the big pharmaceutical companies work, then built a lean generics shop in a college town - no factory, six people, and a strategy of copying the drugs everyone else found too hard.